GLP1R and type 2 diabetes mellitus: While its gene was first cloned in 1983, and protein product approved as a therapeutic agent for Type 2 diabetes mellitus (T2D) in 2005, the mammalian glucagon-like peptide-1 (GLP-1), its modes of action, and various analogs, have been and are still widely studied.